Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/16/22
End: 09/30/23
Due: 09/30/24
Phase: N/A
Priority: Normal
Start: 03/07/23
End: 06/27/24
Due: 06/27/25
Phase: N/A
Priority: Normal
Start: 02/01/21
End: 03/22/23
Due: 03/22/24
Phase: N/A
Priority: Normal
Start: 07/06/22
End: 10/06/23
Due: 10/06/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine | NCT05293665 | Vaxxinity, Inc. | user2@example.com | None | 2022-03-16 | 2023-09-30 | 2024-09-30 | - | - | 2025-07-14 |
| A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants | NCT05762276 | Vaxxinity, Inc. | user2@example.com | None | 2023-03-07 | 2024-06-27 | 2025-06-27 | - | - | 2025-07-14 |
| A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine | NCT04683224 | Vaxxinity, Inc. | user2@example.com | None | 2021-02-01 | 2023-03-22 | 2024-03-22 | - | - | 2025-07-14 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants | NCT05477095 | Vaxxinity, Inc. | user2@example.com | None | 2022-07-06 | 2023-10-06 | 2024-10-06 | - | - | 2025-07-14 |